GlassScriptPhysician profile
Leyda M Su Ham
NPI 1912169657
$2,719.77
in general payments reported to CMS, 2019-2025
13 companies · $588 in 2025
The $588 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49.49 · 2020: $294 · 2021: $298 · 2022: $806 · 2023: $241 · 2024: $443 · 2025: $588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,271.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,101.90 | 2019-2025 | Biktarvy |
| Viiv Healthcare Company | $873.15 | 2020-2025 | Apretude, Cabenuva, Dovato |
| Merck Sharp & Dohme LLC | $330.76 | 2019-2025 | Delstrigo, Pifeltro, Dificid |
| Theratechnologies INC. | $158.92 | 2021-2023 | Trogarzo, Egrifta |
| Janssen Biotech, INC. | $58.28 | 2020-2022 | |
| Glaxosmithkline, LLC. | $53.36 | 2021-2024 | Trelegy Ellipta |
| Abbvie INC. | $33.07 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $25.19 | 2022-2023 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $23.54 | 2022 | |
| Neurocrine Biosciences, INC. | $19.83 | 2020 | |
| Novo Nordisk INC | $15.51 | 2022 | |
| Sunovion Pharmaceuticals INC. | $13.69 | 2020 | |
| Janssen Pharmaceuticals, INC | $12.57 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leyda Su Ham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.